Catalyst Wire Dossier Catalyst Wire Dossier

Alirocumab (Praluent)

alirocumab · Regeneron and Sanofi
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Alirocumab (Praluent), covering 2013-06-28 to 2018-05-01. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) [Phase 4]

See pricing